Botanix Says First Prescriptions Issued for Excessive Sweating Treatment Ahead of Q1 Commercial Launch; Shares Down 3%

MT Newswires Live12-17

Botanix Pharmaceuticals (ASX:BOT) said the first prescriptions for its Sofdra sofpironium topical gel have been issued via telemedicine and insurance approvals, according to a Tuesday filing with the Australian bourse.

Sofdra is approved by the US Food and Drug Administration for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating.

The drug is set for full commercial launch in the first quarter of next year, with inventory, infrastructure, and marketing and sales currently advancing, the filing said.

The company's shares were down almost 3% in recent Tuesday trade.

Price (AUD): $0.37, Change: $-0.01, Percent Change: -2.63%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492067557?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-17 08:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492067557","market":"us","top_or_hot":-1,"title":"Botanix Says First Prescriptions Issued for Excessive Sweating Treatment Ahead of Q1 Commercial Launch; Shares Down 3%","media":"MT Newswires Live","content":"<html><body><p> Botanix Pharmaceuticals (ASX:BOT) said the first prescriptions for its Sofdra sofpironium topical gel have been issued via telemedicine and insurance approvals, according to a Tuesday filing with the Australian bourse.</p><p>Sofdra is approved by the US Food and Drug Administration for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating.</p><p>The drug is set for full commercial launch in the first quarter of next year, with inventory, infrastructure, and marketing and sales currently advancing, the filing said.</p><p>The company's shares were down almost 3% in recent Tuesday trade.</p><p>Price (AUD): $0.37, Change: $-0.01, Percent Change: -2.63%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Botanix Says First Prescriptions Issued for Excessive Sweating Treatment Ahead of Q1 Commercial Launch; Shares Down 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBotanix Says First Prescriptions Issued for Excessive Sweating Treatment Ahead of Q1 Commercial Launch; Shares Down 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-17 08:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Botanix Pharmaceuticals (ASX:BOT) said the first prescriptions for its Sofdra sofpironium topical gel have been issued via telemedicine and insurance approvals, according to a Tuesday filing with the ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7502","symbol_name":"大麻概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492067557","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492067557","pubTimestamp":1734395992,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Botanix Pharmaceuticals  said the first prescriptions for its Sofdra sofpironium topical gel have been issued via telemedicine and insurance approvals, according to a Tuesday filing with the Australian bourse.Sofdra is approved by the US Food and Drug Administration for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating.The drug is set for full commercial launch in the first quarter of next year, with inventory, infrastructure, and marketing and sales currently advancing, the filing said.The company's shares were down almost 3% in recent Tuesday trade.Price : $0.37, Change: $-0.01, Percent Change: -2.63%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7502":"大麻概念","LU0994945656.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC 2","BK4125":"广播","LU1043141123.HKD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (HKD) INC 2","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","AUD":"Audacy Inc.","LU0426417589.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC","LU0426412945.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) ACC","BK7096":"制药","BK7508":"医药生物股","BOT.AU":"BOTANIX PHARMACEUTICALS LTD","LU2238339852.HKD":"NINETY ONE GSF GLOBAL ENVIRONMENT \"A\" (HKD) ACC"},"translate_title":"Botanix表示，在第一季度商业上市之前，首次开出了治疗过度出汗的处方；股价下跌3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUD":1,"BOT.AU":0.9},"content_text":"Botanix Pharmaceuticals (ASX:BOT) said the first prescriptions for its Sofdra sofpironium topical gel have been issued via telemedicine and insurance approvals, according to a Tuesday filing with the Australian bourse.Sofdra is approved by the US Food and Drug Administration for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating.The drug is set for full commercial launch in the first quarter of next year, with inventory, infrastructure, and marketing and sales currently advancing, the filing said.The company's shares were down almost 3% in recent Tuesday trade.Price (AUD): $0.37, Change: $-0.01, Percent Change: -2.63%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492067557"}